Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: Jenna who wrote (12191)	7/28/1998 12:38:00 PM
From: Highway Jim	Read Replies (1) \| Respond to of 120523

Jenna, any thoughts on SEEK or GMGI? Thanks JIm

To: Jenna who wrote (12191)	7/28/1998 1:05:00 PM
From: Jenna	Read Replies (1) \| Respond to of 120523

More on IDGB* *PATH seems that 50 large blocks have gone through today on this company. Interest has been awakened in institutions and mutual funds. I'm not averse to selling off this afternoon and getting back into cash. The market is down quite a bit and even 'good' stocks are falling victim. I'm considering selling MECK, NSOL and MRVC in the next hour or so if the market doesn't rebound. ************************************************************** AmeriPath Reports 75 Percent Net Revenue Growth for the Second Quarter RIVIERA BEACH, Fla., July 28 /PRNewswire/ -- AmeriPath, Inc. (Nasdaq: PATH - news), a physician practice management company focused on anatomic pathology services today reported net revenue growth of 75 percent for the second quarter ended June 30, 1998, compared to the second quarter of the prior year. Net revenue for the second quarter of 1998 was $40.8 million, compared to the second quarter of the prior year of $23.3 million, an increase of 75 percent. Same practice net revenue for the second quarter ended June 30, 1998 increased by $3.2 million or 13.8 percent over the second quarter of the prior year. The remaining increase of $14.3 million resulted from acquisitions completed subsequent to the quarter ended June 30, 1997. Income from operations for the quarter was $9.8 million, up 92 percent over the $5.1 million reported in the comparable period in 1997. Net income was $4.5 million compared to $1.7 million, before a nonrecurring charge of $1.3 million, for the same period last year. For the second quarter of 1998, net income increased to $0.22 per share, based on 20.7 million weighted average shares outstanding, compared to $0.08 per share based on 12.1 million weighted average shares outstanding for the same period of 1997. For the first six months of 1998, AmeriPath reported net revenues of $78.8 million, an increase of 74 percent from the $45.3 million reported for the same period in 1997. Same practice net revenues for the six month period increased by $6.3 million, or 14.1 percent. Approximately 6.5 percent of the increase was attributable to the expansion of a contract with a national laboratory in Florida and 2.5 percent to the increase in Medicare reimbursement which was effective January 1, 1998. Net income for the period was $8.3 million, or $0.40 per share for the six month period, compared to $2.3 million, or $0.19 per share, for the same period in 1997. Annualized net revenue per pathologist of $1.0 million is still running slightly higher than the previous year. The weighted average number of shares outstanding for the six months ended June 30, 1998 was 20.6 million, compared to 12.0 million in the prior year. During the first six months of 1998, AmeriPath acquired eight pathology practices expanding its market presence in Florida, Indiana, Texas, Mississippi and Wisconsin. These acquisitions, including the recently announced acquisition in San Antonio, Texas, added approximately $28 million to theCompany's annual net revenue run rate.